Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultra Low Dose 4 Gy Orbital Radiation for Definitive Therapy of Indolent B Cell Lymphoma
NCT02494700Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2015
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in indolent B-cell lymphoma and mantle cell lymphoma (MCL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Local orbital control at 2 years. Started Jul 2015; status: active, not recruiting.
02
Conditions
indolent B-cell lymphomamantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02494700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02494700.